Response to Comments: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

This document is a response to public comments on the MolDX Local Coverage Determination DL39479 for molecular assays used in diagnosing cutaneous melanoma, listing the comment period (09/29/2022–11/12/2022), notice period start (06/29/2023), and effective date (08/13/2023). The provided text contains only administrative metadata and does not include explicit coverage, limitation, or clinical documentation criteria.

"Document is a response to public comments on MolDX LCD DL39479 (Molecular Assays for Diagnosis of Cutaneous Melanoma); comment period 2022-09-29 to 2022-11-12; notice period begins 2023-06-29; effe..."

Sign up to see full coverage criteria, indications, and limitations.